Floatz logo

ATENOLOL

Treatment Resistant Schizophrenia

All India Institute of Medical Sciences, BhubaneswarSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Treatment Resistant Schizophrenia cohort.

Asset / SponsorPhaseRating
Olanzapine
Dr. Stavroula Rakitzi
Phase 4BB
Risperdal
Dr. Stavroula Rakitzi
Phase 4BB
AMISULPRIDE
University of California, Los Angeles
Phase 4BB
Clozapine
Dr. Stavroula Rakitzi
Phase 4BB
Dextromethorphan
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BB

View all 23 →

Same molecule, other indications

ATENOLOL is also rated in:

myocardial ischemiaDormant
BBB
Indicative ·
75 / 100
View asset →
stroke disorderDormant
BBB
Indicative ·
75 / 100
View asset →
hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →